Dapagliflozin

Dapagliflozin has been studied in 510 papers since 2012: 107 trials and 135 observational studies in people, 107 in animals, 18 in cells, 111 reviews; 355 in the past year. It is an approved medicine. The newest paper, Nov 18, 2026: “Cardiovascular Effects of a Broad Range of Interventions for Adults with Prediabetes: A Systematic Review of Randomized Controlled Trials”.

InterventionSGLT2 inhibitorsApproved 2012

510 papers study it23 more mention it765 findingsUpdated

PubChemChEBIMeSH

123 new papers in 30 daysSee all 518 papers on dapagliflozin

At a glance

Human trials report fewer heart failure events with dapagliflozin, while one trial finds no clear effect on cellular senescence. One group reports improved fly healthspan, and independent labs reproduce lower oxidative stress in mice and lower HbA1c in humans, although a human trial finds no clear HbA1c effect. Some human papers declare ties to developer AstraZeneca.

765 findings in 285 papers from 2012 to 2026, 108 of them since May 2026

Independent labs found the same change in cells, mice and people. 204 independent labs in 37 countries; 406 trials, 124 about aging, 101 with no results posted.

“only high-dose dapagliflozin (10 mg/day) significantly reduced the occurrence of delirium and depression”
The concentration-dependent protective effects by new generation hypoglycemic agents on delirium, depression, dementia and coma: evidence from a network meta-analysisJournal of the Royal Society of Medicine2025doi:10.1177/01410768251395877

55 of its findings point the other way.

Cells, mice and humans: replicated by independent labs. Worms or flies: a single group.
  • 204 independent labs in 37 countries
  • 55 findings against
  • 406 trials, 124 about aging, 101 with no results posted
  • Funders: National Natural Science Foundation of China and others
  • 98 of 730 findings with company ties
  • 162 of 406 trials sponsored by its developers
  • Human trial105
  • Humans134
  • Animals98
  • Model organisms2
  • Cells17
  • In silico10

88 studies gave dapagliflozin to people and measured what changed.

What changedDesignPeopleSource

up: Improves chronic eGFR slopeBetween-group difference 1.7 mL/min/1.73 m2 (95% CI 0.1–3.3); p = 0.03

no change: Has no effect on adverse event rates

Randomized trial2 weeks to 12 months424 peopleBoth53 ± 14 yearsMidlife adults; Heart transplant recipientsCirculation, Nov 8, 2026

up: Increases hematocrit

up: Increases HDL cholesterol

down: Decreases rectus femoris cross-sectional area7.12 to 6.65 cm2

Treated cohort37 peopleMenAdults; median age 60 yearsOlder adults; HIV and chronic kidney diseasePreprints.org, Nov 6, 2026

down: Decreases NT-proBNP−34.2% vs. −25.0%; P = 0.003

Randomized trial72 hours108 peopleadultsHospitalized acute heart failureClinical pharmacology and therapeutics, Nov 3, 2026

down: Decreases hepatic steatosisCAP 310.2 to 287.0 dB/m

down: Decreases liver stiffness measurement−0.46 kPa

Treated cohort25 weeks27 people18–70 yearsMASLDEndocrinology, diabetes & metabolism, Nov 1, 2026

no change: Has no effect on left ventricular mass indexAdjusted mean difference -3.7 g/m2; 95% CI -11.2 to 3.8

down: Decreases left ventricular mass indexAdjusted mean difference −9.2 g/m2; P=0.035

Randomized trial6 months220 peopleBoth65 yrsOlder adults; kidney failure receiving maintenance hemodialysis and left ventricular hypertrophyESC Congress 2026 abstract, Oct 26, 2026

What did studies of dapagliflozin find?

447

Studies of dapagliflozin measured 447 outcomes, among them HbA1c, oxidative stress and ROS signaling and inflammation.

HbA1c

downin humans13no changein humans3

16 studies
  1. Dapagliflozin showed no clear effect on HbA1c in humans (Kidney transplant recipients with post-transplant diabetes mellitus; versus standard care).

    “whereas HbA1c and tacrolimus trough concentrations were similar.”

    Human trialKidney transplant recipients with post-transplant diabetes mellitus; versus standard care10 mg daily54 weeks

    Dapagliflozin and 54-week kidney function in kidney transplant recipients with post-transplant diabetes mellitus: a randomized controlled trial

    Diabetes research and clinical practice

  2. Dapagliflozin decreases HbA1c in humans (as an adjunct to insulin).

    “Similarly, Group B demonstrated reductions of 23.6% in FBG, 25.1% in 2hPBG, and 24.9% in HbA1c.‌ FBG, 2hPBG and HbA1c reductions were significantly greater in Group B than in Group A, indicating superior blood glucose index control.”

    Human trialas an adjunct to insulin3 months post-dischargen = 90

    Dapagliflozin as an adjunct to insulin improves glycemic control, weight, and lipid profile with a superior safety profile in type 2 diabetes: a randomized trial

    Clinics (Sao Paulo, Brazil)

  3. Dapagliflozin decreases HbA1c in humans (adjunct to insulin in type 2 diabetes) (24.9% vs. 10.3%).

    “Reductions in Group B versus Group A were: HbA1c (24.9%vs. 10.3%)”

    Human trialadjunct to insulin in type 2 diabetes3 monthsn = 86

    Dapagliflozin as an adjunct to insulin improves glycemic control, weight, and lipid profile with a superior safety profile in type 2 diabetes: a randomized trial

    Clinics (Sao Paulo, Brazil)

  4. Dapagliflozin decreases HbA1c in humans (added to semaglutide, Period 2 (weeks 26 to 52), vs placebo) (-0.46% HbA1c vs placebo).

    “In Period 2, HbA1c was further reduced by 0.46% (95% CI -0.78, -0.14; p=0.003) by dapagliflozin vs placebo”

    Human trialadded to semaglutide, Period 2 (weeks 26 to 52), vs placebooral10 mg daily26 weeksn = 36

    Triple Therapy for Type 1 Diabetes with Insulin, Semaglutide, and Dapagliflozin (TTT1): A Phase 3 Clinical Trial

    ADA Scientific Sessions 2026 abstract

  5. Dapagliflozin showed no clear effect on HbA1c in humans (fell by 0.8% in both groups).

    “HbA1c fell by 0.8% in both groups with no between-group difference (p = 0.887), although fasting plasma glucose, fasting insulin, and HOMA2 dropped significantly in dapagliflozin arm..”

    Human trial12 weeksn = 98

    Dapagliflozin-induced integrated improvements in left ventricular diastole, endothelial function, and arterial load: a randomized clinical trial

    Cardiovascular diabetology

  6. Dapagliflozin showed no clear effect on HbA1c in humans (type 2 diabetes) (between-group p = 0.887).

    “glycemic control improved similarly in both groups (median [IQR] HbA1c change: -0.78 [0.11]% vs. -0.80 [0.10]%; between-group p = 0.887).”

    Human trialtype 2 diabetes12 weeksn = 96

    Dapagliflozin-induced integrated improvements in left ventricular diastole, endothelial function, and arterial load: a randomized clinical trial

    Cardiovascular diabetology

  7. Dapagliflozin decreases HbA1c in humans (type 2 diabetes; compared with placebo) (-0.52 vs. 0.11; p = 0.012).

    “dapagliflozin resulted in reduction in liver MRI-PDFF (-3.7% vs. 0.5%, p = 0.001), body weight (-3.84 vs. -1.42 kg, p = 0.015), and HbA1c (-0.52 vs. 0.11, p = 0.012).”

    Human trialtype 2 diabetes; compared with placebo10 mg12 monthsn = 56

    Dapagliflozin-Associated Reduction in Liver Fat Is Independent of Weight Loss in Patients With Type 2 Diabetes

    Obesity (Silver Spring, Md.)

  8. Dapagliflozin decreases HbA1c in humans (newly diagnosed T2DM patients with evidence of micro- or macro-albuminuria) (from 9.04% to 7.31% (P < 0.001)).

    “Glycemic control was rapidly achieved, with a mean HbA1c drop from 9.04% to 7.31% (P < 0.001).”

    Human trialnewly diagnosed T2DM patients with evidence of micro- or macro-albuminuria10 mg/day3 monthsn = 133

    Acute renoprotective effects of dapagliflozin monotherapy on albuminuria and metabolic derangements in newly diagnosed type 2 diabetes mellitus: a quasi-experimental study

    Diabetology & metabolic syndrome

  9. Dapagliflozin showed no clear effect on HbA1c in humans.

    “This indicates that HbA1c levels decreased significantly throughout the treatment period regardless of the therapeutic regimen employed, yet no differences were observed between the three treatment groups in their efficacy or rate of HbA1c reduction.”

    Human trialn = 81

    The Impact of Different Oral Antidiabetic Drugs on Insulin Pump Intensive Therapy in Type 2 Diabetes Patients: A Clinical Study

    Journal of diabetes research

  10. Dapagliflozin decreases HbA1c in humans.

    “Subsequent assessment demonstrated improved HgbA1C, fasting glucose, insulin, and C-peptide concentrations.”

    Human trial2-4 yearsn = 6

    The Use of Dapagliflozin in the Treatment of Children With Severe Insulin Resistance

    Pediatric diabetes

All 18

More on HbA1c

Oxidative stress and ROS signaling

downin rats7downin mice3downin human cells2downin humans2+2

16 studies
  1. Dapagliflozin decreases oxidative stress and ROS signaling in humans (mean difference: +115 ng/mL, 95% CI: 39 to 191 ng/mL, P = 0.0047).

    “After treatment, MPO (mean difference: +115 ng/mL, 95% confidence interval (CI): 39 to 191 ng/mL, P = 0.0047), MMP-1 (mean difference: +306 ng/mL, 95% CI: 124 to 488 ng/mL, P = 0.0021), and MMP-9 (mean difference: +6,196 ng/mL, 95% CI: 670 to 11,721 ng/mL, P = 0.029) levels significantly decreased, whereas MMP-2 (mean difference: +723 ng/mL, 95% CI: -1,280 to 2,726 ng/mL, P = 0.46) showed no significant change”

    Human trial6 monthsn = 25

    Anti-Oxidative Effect of Dapagliflozin, a Selective Sodium Glucose Transporter-2 Inhibitor, for Cardio-Renal Protection in Patients With Heart Failure With Reduced Ejection Fraction

    Cardiology research

  2. Dapagliflozin decreases oxidative stress and ROS signaling in humans (heart failure with reduced ejection fraction).

    “oxidative stress markers including myeloperoxidase, matrix metalloproteinase-1, and matrix metalloproteinase-9 significantly improved”

    Human trialheart failure with reduced ejection fraction6 months

    Anti-Oxidative Effect of Dapagliflozin, a Selective Sodium Glucose Transporter-2 Inhibitor, for Cardio-Renal Protection in Patients With Heart Failure With Reduced Ejection Fraction

    Cardiology research

  3. Dapagliflozin decreases oxidative stress and ROS signaling in human cells with alpelisib and fulvestrant under hyperglycemia.

    “Transcriptomic analysis confirmed coordinated downregulation of oxidative stress, inflammatory, and insulin-stress pathways.”

    Cellswith alpelisib and fulvestrant under hyperglycemiaiPSC-derived cardiomyocytes

    SGLT2 inhibitor dapagliflozin attenuates cardiomyocyte injury and inflammation induced by PI3Kα-selective inhibitor alpelisib and fulvestrant under hyperglycemia

    ESC Congress 2026 abstract

  4. Dapagliflozin inhibits oxidative stress and ROS signaling in rats (against DOX-related cardiotoxicity).

    “Cardiotoxicity is better controlled with DAPA than Cr by suppressing oxidative stress, apoptosis, and upregulation of the antioxidant Nrf-2/HO-1/NQO1 genes.”

    Animalsagainst DOX-related cardiotoxicityheart12 weeksmales

    Dapagliflozin and crocin ameliorate DOX-induced cardiotoxicity in rats via activating the Nrf-2/HO-1/NQO1 pathway: a comparative study

    Immunopharmacology and immunotoxicology

  5. Dapagliflozin decreases oxidative stress and ROS signaling in rats (isoproterenol-induced myocardial injury).

    “DAPA significantly reduced ISO-induced elevations in cardiac troponin-I, creatine kinase-MB, lactate dehydrogenase, and oxidative stress markers”

    Animalsisoproterenol-induced myocardial injuryheart1 mg/kg/day14 daysmales

    Cardioprotective Effects of Dapagliflozin against Isoproterenol-induced Myocardial Injury in Rats: Biochemical and Histopathological Evidence

    International journal of applied & basic medical research

  6. Dapagliflozin decreases oxidative stress and ROS signaling in cells (myocardial IRI).

    “Dapa upregulates EGFR phosphorylation, suppresses NHE1 expression in myocardial tissues, modulates NCOA4-mediated ferritinophagy to enhance mitochondrial function, reduces ROS expression, and mitigates myocardial IRI.”

    Cellsmyocardial IRImyocardium

    Dapagliflozin ameliorates myocardial ischemia/reperfusion injury by modulating EGFR signaling and targeting NCOA4-mediated ferritinophagy

    Life sciences

  7. Dapagliflozin decreases oxidative stress and ROS signaling in rats (propylthiouracil-induced hypothyroidism).

    “Hypothyroidism induced oxidative stress associated mitophagy disturbance in both lung and liver with development of apoptosis in liver. DAPA avoided this effect”

    Animalspropylthiouracil-induced hypothyroidismlung and liver1 mg/kg/dayfive weeks

    Dapagliflozin attenuates hypothyroidism induced liver and lung dysfunction via regulation of mitophagy and apoptosis

    Molecular biology reports

  8. Dapagliflozin decreases oxidative stress and ROS signaling in mice under chronic stress.

    “reduced inflammation and oxidative stress and inhibited apoptosis in the aorta and HUVECs”

    Animalsunder chronic stress

    Dapagliflozin Attenuates Atherosclerosis Under Chronic Stress by Maintaining AKT/FoxO1 Pathway Through Downregulation of REDD1

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology

  9. Dapagliflozin induces oxidative stress and ROS signaling in chickens.

    “intracellular oxidative stress is confirmed by SOD and CAT assays, implicating oxidative stress as a central mediator of these abnormalities”

    Animalsheart1.0-2.5 mg/mL

    Embryotoxic and Oxidative Impact of Dapagliflozin: A Dose-Dependent Study Using a Chick Embryo Model

    Journal of applied toxicology : JAT

  10. Dapagliflozin decreases oxidative stress and ROS signaling in rats (myocardial ischemia/reperfusion injury).

    “DAPA reduced oxidative stress by decreasing malondialdehyde (MDA) levels and increasing superoxide dismutase (SOD) activity.”

    Animalsmyocardial ischemia/reperfusion injury1 mg/kg/day14 daysmales

    Dapagliflozin Reduces Myocardial Injuries Through Modulation of H3K27me3 and SIRT1 in the Male Rat Model of Myocardial Ischemia Reperfusion

    Journal of cardiovascular pharmacology

All 17

More on Oxidative stress and ROS signaling

Inflammation

downin rats9downin mice4downin human cells1downin humans1

15 studies
  1. Dapagliflozin decreases inflammation in humans.

    “On the other hand, white blood cells, alanine aminotransferase, ferritin, CRP, brain natriuretic peptide, urinary N-acetyl-β-D-glycosaminidase, and urinary creatinine significantly decreased after treatment.”

    Human trial6 monthsn = 25

    Anti-Oxidative Effect of Dapagliflozin, a Selective Sodium Glucose Transporter-2 Inhibitor, for Cardio-Renal Protection in Patients With Heart Failure With Reduced Ejection Fraction

    Cardiology research

  2. Dapagliflozin decreases inflammation in mice (experimental myocardial infarction).

    “Histological analyses (H&E and Masson staining) revealed attenuated inflammatory infiltration and myocardial fibrosis in DAPA-treated mice.”

    Animalsexperimental myocardial infarctionheart

    Dapagliflozin attenuates post-infarction inflammation and remodeling via promoting metabolic reprogramming–driven cardiac lymphangiogenesis

    ESC Congress 2026 abstract

  3. Dapagliflozin decreases inflammation in aortic stenosis rats.

    “Myocardial concentration of the cytokines IL-1β, IL-6, IL-10 and TNF-α was higher in AS than Sham and AS-Dapa.”

    Animalsin aortic stenosis ratsheart12 weeksmales

    Influence of dapagliflozin on cardiac remodeling in aortic stenosis rats: functional assessment and inflammatory and autophagic pathways evaluation

    ESC Congress 2026 abstract

  4. Dapagliflozin decreases inflammation in a rat model of myocardial infarction-induced heart failure.

    “In vivo, DAPA suppressed myocardial STAT1 expression, alleviated inflammation, normalized macrophage polarization, and reduced cytokine and bile acid abnormalities.”

    Animalsin a rat model of myocardial infarction-induced heart failuremyocardium6 mg/kg/day4 weeks

    Dapagliflozin mitigates myocardial inflammation and metabolic stress in heart failure through STAT1 inhibition: Evidence from multi-omics analyses and experimental exploration

    PloS one

  5. Dapagliflozin decreases inflammation in rats (methotrexate-induced liver injury).

    “suppressed inflammatory and apoptotic markers”

    Animalsmethotrexate-induced liver injuryliver10 mg/kg/day10 daysfemales

    Cellular Anti-Apoptotic Effects of Dapagliflozin in Methotrexate-Induced Liver Toxicity: Bax/Bcl-2/Cyt-C/Cas-9/Cas-3 Signaling Pathway

    International journal of molecular sciences

  6. Dapagliflozin decreases inflammation in rats (isoproterenol-induced myocardial injury).

    “DAPA also attenuated inflammatory cytokines: tumor necrosis factor-alpha and interleukin-6 (IL-6).”

    Animalsisoproterenol-induced myocardial injury1 mg/kg/day14 daysmales

    Cardioprotective Effects of Dapagliflozin against Isoproterenol-induced Myocardial Injury in Rats: Biochemical and Histopathological Evidence

    International journal of applied & basic medical research

  7. Dapagliflozin decreases inflammation in diabetic db/db mice.

    “Fibrosis and inflammation-associated pathways in SMC and fibroblasts, and dysfunction markers in endothelial cells, increased in diabetes and were partly reversed by DAPA.”

    Animalsin diabetic db/db miceaorta6 weeks

    Single-Cell Multimodal Profiling Highlights Persistent Aortic Smooth Muscle Cell Changes in Diabetic Mice Despite Glycemic Control

    Arteriosclerosis, thrombosis, and vascular biology

  8. Dapagliflozin decreases inflammation in mice under chronic stress.

    “reduced inflammation and oxidative stress and inhibited apoptosis in the aorta and HUVECs”

    Animalsunder chronic stress

    Dapagliflozin Attenuates Atherosclerosis Under Chronic Stress by Maintaining AKT/FoxO1 Pathway Through Downregulation of REDD1

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology

  9. Dapagliflozin decreases inflammation in rats (myocardial ischemia/reperfusion injury).

    “reduced myocardial inflammation by improving myocardial TNF-α, NF-κB, IL-1β, and IL-6.”

    Animalsmyocardial ischemia/reperfusion injurymyocardium1 mg/kg/day14 daysmales

    Dapagliflozin Reduces Myocardial Injuries Through Modulation of H3K27me3 and SIRT1 in the Male Rat Model of Myocardial Ischemia Reperfusion

    Journal of cardiovascular pharmacology

  10. Dapagliflozin decreases inflammation in mice (HFD/STZ-induced T2DM mice).

    “effectively inhibit neuroinflammation (significantly reduced levels of tumor necrosis factor-α, interleukin-1β, and interleukin-6)”

    AnimalsHFD/STZ-induced T2DM mice

    Dapagliflozin regulates kynurenine metabolism and microglial activation to alleviate diabetes-associated cognitive impairment

    Toxicology and applied pharmacology

All 15

More on Inflammation

Body weight

downin humans9downin chickens1upin humans1downin rats1+2−47%

14 studies
  1. Dapagliflozin decreases body weight in humans (as an adjunct to insulin) (-5.4% vs -3.3%).

    “Group A showed reductions of 3.2% in SBP, 7.8% in DBP, 4.3% in BMI and 3.3% in BW, while Group B demonstrated significantly greater reductions (7.3% in SBP, 12.6% in DBP, 9.8% in BMI and 5.4% in BW).”

    Human trialas an adjunct to insulin3 months post-dischargen = 90

    Dapagliflozin as an adjunct to insulin improves glycemic control, weight, and lipid profile with a superior safety profile in type 2 diabetes: a randomized trial

    Clinics (Sao Paulo, Brazil)

  2. Dapagliflozin improves body weight in T2DM patients with MASLD.

    “Improvements were also observed in glycaemic control, body weight, lipid profile, liver enzymes, ultrasonographic steatosis grading, and serum fibrosis markers.”

    Human trialin T2DM patients with MASLD10 mg daily12 monthsn = 50

    Efficacy of dapagliflozin on hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: a pre-specified single-arm analysis from a randomized controlled trial

    Diabetes research and clinical practice

  3. Dapagliflozin decreases body weight in humans (type 2 diabetes; compared with placebo) (-3.84 vs. -1.42 kg; p = 0.015).

    “dapagliflozin resulted in reduction in liver MRI-PDFF (-3.7% vs. 0.5%, p = 0.001), body weight (-3.84 vs. -1.42 kg, p = 0.015)”

    Human trialtype 2 diabetes; compared with placebo10 mg12 monthsn = 56

    Dapagliflozin-Associated Reduction in Liver Fat Is Independent of Weight Loss in Patients With Type 2 Diabetes

    Obesity (Silver Spring, Md.)

  4. Dapagliflozin decreases body weight in obese patients with T2DM without established cardiovascular disease.

    “Participants experienced statistically significant reductions in their HbA1c, fasting plasma glucose, low-density lipoprotein cholesterol, total cholesterol, body weight, BMI, WHR, BFM, and aortic PWV”

    Human trialin obese patients with T2DM without established cardiovascular disease10 mg daily6 months

    SAT-587 The Effects of Dapagliflozin on Diabetes Mellitus without Cardiovascular Disease

    ENDO 2025 abstract

  5. Dapagliflozin decreases body weight in humans (-4 kg).

    “DAPA and MET resulted in -4kg weight loss”

    Human trial1 yearn = 47

    Beta-Cell Preservation with Early Oral Antidiabetic Medications in Prediabetes (PreDM)

    ADA Scientific Sessions 2025 abstract

  6. Dapagliflozin decreases body weight in humans (−1.3 kg, 95% CI −1.9 to −0.7 kg).

    “We found a significant difference between the two groups in weight change (−1.3 (95% CI −1.9 to −0.7) kg).”

    Human trial12 monthsn = 328

    Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial

    BMJ (Clinical research ed.)

  7. Dapagliflozin decreases body weight in humans with calorie restriction (difference -1.3 (95% CI -1.9 to -0.7) kg).

    “Changes in body weight (difference -1.3 (95% CI -1.9 to -0.7) kg) and homoeostasis model assessment of insulin resistance (difference -0.8, -1.1 to -0.4) were significantly greater in the dapagliflozin group”

    Human trialwith calorie restriction10 mg/day12 monthsn = 328

    Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial

    BMJ (Clinical research ed.)

  8. Dapagliflozin decreases body weight in humans (vs placebo) (1·5 kg (0·03-3·0)).

    “Compared with placebo, bodyweight was reduced by 1·5 kg (0·03-3·0; p=0·046) with dapagliflozin”

    Human trialvs placebo10 mg per day6 weeksn = 53

    Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial

    The lancet. Diabetes & endocrinology

  9. Dapagliflozin is linked with lower body weight in humans.

    “Dapagliflozin therapy was associated with significant improvements in body weight, BMI, and blood pressure at 6 months in both groups”

    Humans6 months

    Phytotherapeutic Supplementation with Momordica charantia: Beneficial Effects in Patients with Suboptimal Glycemic Control on Double Antidiabetic Therapy-A Real-World Evidence Observational Study

    Nutrients

  10. Dapagliflozin is linked with lower body weight in humans (real-world HFrEF patients) (P < .001).

    “with significant reductions in body weight and heart rate (P < .001)”

    Humansreal-world HFrEF patients15.3 ± 8.3 monthsn = 155

    Impact of Dapagliflozin on Heart Failure with Reduced Ejection Fraction: A Real-World Study

    Journal of clinical pharmacology

All 15

Cellular senescence

downin human cells6downin mice5downin rats2no changein humans1+1

12 studies
  1. Dapagliflozin showed no clear effect on cellular senescence in humans.

    “There were no significant changes in these markers.”

    Human trial6 monthsn = 25

    Anti-Oxidative Effect of Dapagliflozin, a Selective Sodium Glucose Transporter-2 Inhibitor, for Cardio-Renal Protection in Patients With Heart Failure With Reduced Ejection Fraction

    Cardiology research

  2. Dapagliflozin decreases cellular senescence in high glucose-treated HK-2 cells.

    “Dapagliflozin reduced the expression of renal senescence markers in both in vivo and in vitro experiments.”

    Cellsin high glucose-treated HK-2 cells

    Dapagliflozin attenuates cellular senescence and mitochondrial dysfunction in diabetic kidney disease: potential involvement of AMPK/Sirt3 signaling

    Biochemical pharmacology

  3. Dapagliflozin decreases cellular senescence in streptozotocin-induced diabetic mice.

    “Dapagliflozin reduced the expression of renal senescence markers in both in vivo and in vitro experiments.”

    Animalsin streptozotocin-induced diabetic micekidney

    Dapagliflozin attenuates cellular senescence and mitochondrial dysfunction in diabetic kidney disease: potential involvement of AMPK/Sirt3 signaling

    Biochemical pharmacology

  4. Dapagliflozin decreases cellular senescence in rats (HFD/STZ/UNx-induced DKD).

    “dapagliflozin (0.1 mg/kg/day) improved metabolic abnormalities and renal dysfunction and attenuated tubular senescence”

    AnimalsHFD/STZ/UNx-induced DKDkidney tubule0.1 mg/kg/day

    SGLT2 Inhibition Attenuates Renal Tubular Senescence by Suppressing CTRP1-Mediated Glucotoxic Stress in Diabetic Kidney Disease

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology

  5. Dapagliflozin decreases cellular senescence in TAA-induced rats.

    “Mechanistically, both drugs suppressed fibrotic and senescence markers, downregulated PD-1, enhanced sirtuin-1, and mitigated oxidative stress.”

    Animalsin TAA-induced ratslivermales

    Dual Modulation of Senescence and Immune Checkpoints by Metformin and Dapagliflozin Attenuates Liver Fibrosis in a Thioacetamide-Induced Rat Model

    Advanced pharmaceutical bulletin

  6. Dapagliflozin decreases cellular senescence in human cells under high-fat conditions.

    “by which the accumulation of senescent cells in human aortic smooth muscle cells (HASMCs) was reduced under high-fat conditions”

    Cellsunder high-fat conditions

    Inhibition of the RXRA-PPARα-FABP4 signaling pathway alleviates vascular cellular aging by an SGLT2 inhibitor in an atherosclerotic mice model

    Science China. Life sciences

  7. Dapagliflozin decreases cellular senescence in ApoE-/- mice (16.4%±3.7% vs. 30.7%±2.0% (P<0.01)).

    “the percentage of senescent cells within the plaques (16.4%±3.7% vs. 30.7%±2.0%, P<0.01)”

    Animalsin ApoE-/- miceaorta0.1 mg kg−1 d−114 weeks

    Inhibition of the RXRA-PPARα-FABP4 signaling pathway alleviates vascular cellular aging by an SGLT2 inhibitor in an atherosclerotic mice model

    Science China. Life sciences

  8. Dapagliflozin decreases cellular senescence in human cells (H2O2-induced senescence in HK-2 cells).

    “Senescent human proximal tubular epithelial (HK-2) cells induced by H2 O2 also exhibit lower senescent markers after dapagliflozin treatment.”

    CellsH2O2-induced senescence in HK-2 cells

    SGLT2i improves kidney senescence by down-regulating the expression of LTBP2 in SAMP8 mice

    Journal of cellular and molecular medicine

  9. Dapagliflozin decreases cellular senescence in mice (natural kidney senescence in SAMP8 mice).

    “inhibiting expression of senescence-related biomarkers”

    Animalsnatural kidney senescence in SAMP8 micekidney4 months

    SGLT2i improves kidney senescence by down-regulating the expression of LTBP2 in SAMP8 mice

    Journal of cellular and molecular medicine

  10. Dapagliflozin decreases cellular senescence in HG-induced T2D mouse model (significantly reduced senescence activity in mouse aortas).

    “mouse aortas had significantly reduced levels of senescence activity and senescence-associated inflammatory factors”

    Animalsin HG-induced T2D mouse modelaorta

    Dapagliflozin impedes endothelial cell senescence by activating the SIRT1 signaling pathway in type 2 diabetes

    Heliyon

All 15

More on Cellular senescence

Apoptosis

downin rats8downin human cells2upin human cells1downin mice1

12 studies
  1. Dapagliflozin increases apoptosis in human cells (combined with doxorubicin–trastuzumab in HER2-positive breast cancer cells) (p < 0.001).

    “Both canagliflozin and dapagliflozin significantly enhanced the cytotoxicity of doxorubicin–trastuzumab in HER2-positive breast cancer cells, as evidenced by reduced proliferation and increased apoptotic activity (p < 0.001).”

    Cellscombined with doxorubicin–trastuzumab in HER2-positive breast cancer cellsHER2-positive breast cancer cells (BT-474, SKBR3)5 μM

    Pleiotropic effects of canagliflozin and dapagliflozin in cadio-oncology: a novel strategy to balance antitumor efficacy and cardiotoxicity in HER2-positive breast cancer therapy

    ESC Congress 2026 abstract

  2. Dapagliflozin inhibits apoptosis in rats (against DOX-related cardiotoxicity).

    “Cardiotoxicity is better controlled with DAPA than Cr by suppressing oxidative stress, apoptosis, and upregulation of the antioxidant Nrf-2/HO-1/NQO1 genes.”

    Animalsagainst DOX-related cardiotoxicityheart12 weeksmales

    Dapagliflozin and crocin ameliorate DOX-induced cardiotoxicity in rats via activating the Nrf-2/HO-1/NQO1 pathway: a comparative study

    Immunopharmacology and immunotoxicology

  3. Dapagliflozin decreases apoptosis in rats (methotrexate-induced liver injury).

    “suppressed inflammatory and apoptotic markers”

    Animalsmethotrexate-induced liver injuryliver10 mg/kg/day10 daysfemales

    Cellular Anti-Apoptotic Effects of Dapagliflozin in Methotrexate-Induced Liver Toxicity: Bax/Bcl-2/Cyt-C/Cas-9/Cas-3 Signaling Pathway

    International journal of molecular sciences

  4. Dapagliflozin inhibits apoptosis in rats (isoproterenol-induced myocardial injury).

    “DAPA downregulated the pro-apoptotic protein (Bax) expression and upregulated the anti-apoptotic protein (Bcl2) levels in the heart.”

    Animalsisoproterenol-induced myocardial injuryheart1 mg/kg/day14 daysmales

    Cardioprotective Effects of Dapagliflozin against Isoproterenol-induced Myocardial Injury in Rats: Biochemical and Histopathological Evidence

    International journal of applied & basic medical research

  5. Dapagliflozin prevents apoptosis in rats (propylthiouracil-induced hypothyroidism).

    “Hypothyroidism induced oxidative stress associated mitophagy disturbance in both lung and liver with development of apoptosis in liver. DAPA avoided this effect”

    Animalspropylthiouracil-induced hypothyroidismliver1 mg/kg/dayfive weeks

    Dapagliflozin attenuates hypothyroidism induced liver and lung dysfunction via regulation of mitophagy and apoptosis

    Molecular biology reports

  6. Dapagliflozin inhibits apoptosis in mice under chronic stress.

    “reduced inflammation and oxidative stress and inhibited apoptosis in the aorta and HUVECs”

    Animalsunder chronic stress

    Dapagliflozin Attenuates Atherosclerosis Under Chronic Stress by Maintaining AKT/FoxO1 Pathway Through Downregulation of REDD1

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology

  7. Dapagliflozin decreases apoptosis in rats (cisplatin-treated rats).

    “DAPA attenuated oxidative stress, inflammation, and apoptotic pathways.”

    Animalscisplatin-treated ratsbrain1 mg/kg/day4 weeksmalesn = 40

    Dapagliflozin ameliorates cisplatin-induced cognitive impairments in rats: Cross-talk between miRNA-21/p-ERK/p-38 MAPK and wnt/β-catenin signaling pathways

    Neurotoxicology

  8. Dapagliflozin decreases apoptosis in rats (doxorubicin-induced apoptosis).

    “Further evidence of DAPA's anti-apoptotic effects was attributed to a decrease in the immunohistochemical expression of total caspase-3”

    Animalsdoxorubicin-induced apoptosis2 mg/kg28 consecutive days

    Dapagliflozin Ameliorates Doxorubicin-Induced Chemobrain and Cognitive Abnormalities in Rats: Modulation of AKT/GSK-3β and Wnt/β-Catenin Pathways

    Neurochemical research

  9. Dapagliflozin decreases apoptosis in rats after coronary microembolization.

    “Heart dysfunction and tissue damage caused by CME can be alleviated by pre-treatment with DAPA, which also reduces myocardial inflammation and apoptosis.”

    Animalsafter coronary microembolizationmyocardium

    Dapagliflozin Attenuates Myocardial Inflammation and Apoptosis after Coronary Microembolization in Rats by Regulating the SIRT1/NF-κB Signaling Pathway

    Frontiers in bioscience (Landmark edition)

  10. Dapagliflozin protects against apoptosis in rats (lipopolysaccharide-induced acute lung injury).

    “DPG exhibited protective effects against inflammation, oxidative stress, and subsequent apoptosis”

    Animalslipopolysaccharide-induced acute lung injurylung10 mg/kgfive consecutive days

    Protective effect of dapagliflozin on lipopolysaccharide-induced acute lung injury via the SIRT-1/PGC-1α pathway

    Molecular biology reports

All 12

More on Apoptosis

Left ventricular ejection fraction

upin humans7no changein humans3upin rats1

11 studies
  1. Dapagliflozin showed no clear effect on left ventricular ejection fraction in humans (at 3 months, compared with placebo) (dapagliflozin +5.4±10.1%; placebo +3.6±14.2%).

    “LVEF improved significantly in both groups without a between-group difference”

    Human trialat 3 months, compared with placeboleft ventricle20 mg loading dose before wire crossing, then 10 mg daily3 months

    Dapagliflozin showed no clear reduction in heart attack size

    ESC Congress 2026 abstract

  2. Dapagliflozin showed no clear effect on left ventricular ejection fraction in humans (at 12 weeks post-PCI, compared with placebo).

    “LVEF did not differ between groups at 12 weeks post-PCI”

    Human trialat 12 weeks post-PCI, compared with placeboheart20 mg loading dose followed by 10 mg daily12 weeks

    Dapagliflozin improved blood-cell resistance to energy stress

    ESC Congress 2026 abstract

  3. Dapagliflozin improves left ventricular ejection fraction in humans (type 2 diabetes mellitus) (+0.8%, p = .003).

    “Left ventricular ejection fraction (LVEF) improved modestly (+0.8%, p = .003)”

    Human trialtype 2 diabetes mellitus3 monthsn = 700

    Effect of dapagliflozin on electrocardiographic arrhythmic markers in patients with type 2 diabetes mellitus

    British journal of clinical pharmacology

  4. Dapagliflozin increases left ventricular ejection fraction in humans (STEMI undergoing primary PCI; baseline LVEF ≤40%; without diabetes or heart failure) (41.1 ± 5.5 vs. 38.1 ± 6.9; P = 0.037).

    “a significant increase in LVEF in dapagliflozin-treated patients with baseline LVEF ≤40% compared with the placebo group”

    Human trialSTEMI undergoing primary PCI; baseline LVEF ≤40%; without diabetes or heart failureheart10 mg/d40 days

    Dapagliflozin Effects in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: The DAPA-STEMI Randomized Clinical Trial

    American journal of therapeutics

  5. Dapagliflozin improves left ventricular ejection fraction in humans.

    “LVEF was significantly increased.”

    Human trial6 monthsn = 25

    Anti-Oxidative Effect of Dapagliflozin, a Selective Sodium Glucose Transporter-2 Inhibitor, for Cardio-Renal Protection in Patients With Heart Failure With Reduced Ejection Fraction

    Cardiology research

  6. Dapagliflozin increases left ventricular ejection fraction in humans.

    “Both cohorts demonstrated significant within-group improvements in LVEF, LV volumes, and GLS, with greater remodeling benefits observed in the dapagliflozin arm.”

    Human trialsix monthsn = 200

    Early Dapagliflozin in Non-diabetic Acute Myocardial Infarction Patients Post-PCI: Effects on Cardiovascular Outcomes and Left Ventricular Remodeling (EARLY DAPA-AMI)

    Journal of the Saudi Heart Association

  7. Dapagliflozin improves left ventricular ejection fraction in humans (heart failure with preserved ejection fraction) (p < 0.05).

    “At 12-month follow-up, the dapagliflozin group exhibited significant increases in left ventricular ejection fraction”

    Human trialheart failure with preserved ejection fraction12 monthsfemalesn = 150

    Effects of dapagliflozin on ventricular remodeling and prognosis in older females with heart failure with preserved ejection fraction: A single-center prospective study

    Experimental gerontology

  8. Dapagliflozin is linked with better left ventricular ejection fraction in humans (acute heart failure) (48.36% ± 4.88% vs. 43.85% ± 4.90%).

    “left ventricular ejection fraction (48.36% ± 4.88% vs. 43.85% ± 4.90%, P = 0.002)”

    Humansacute heart failure10 mg once daily6 months

    Metabolic remodeling and cardiac functional adaptation mediated by dapagliflozin in patients with acute heart failure: a retrospective cohort study

    Frontiers in pharmacology

  9. Dapagliflozin was not clearly linked with left ventricular ejection fraction in humans (perioperative use before mitral valve replacement, compared with control group).

    “there were no significant differences in the percentage changes in pulmonary artery systolic pressure (PASP), left ventricular ejection fraction (LVEF), right ventricular function (TAPSE)”

    Humansperioperative use before mitral valve replacement, compared with control groupleft ventriclen = 196

    Effects of dapagliflozin on main pulmonary artery diameter in patients undergoing mitral valve replacement: a retrospective observational study

    Frontiers in cardiovascular medicine

  10. Dapagliflozin is linked with better left ventricular ejection fraction in humans (real-world HFrEF patients) (from 29.2% to 34.3% (P < .001)).

    “LVEF improved from 29.2% to 34.3% (P < .001)”

    Humansreal-world HFrEF patients15.3 ± 8.3 monthsn = 155

    Impact of Dapagliflozin on Heart Failure with Reduced Ejection Fraction: A Real-World Study

    Journal of clinical pharmacology

All 11

NT-proBNP

downin humans6no changein humans1upin humans1

8 studies
  1. Dapagliflozin decreases NT-proBNP in humans (Hospitalized acute heart failure; compared with acetazolamide alongside standard care) (−34.2% vs. −25.0%; P = 0.003).

    “Dapagliflozin achieved a larger reduction in N‐terminal pro‐B‐type natriuretic peptide at 72 hours (−34.2% vs. −25.0%; P = 0.003).”

    Human trialHospitalized acute heart failure; compared with acetazolamide alongside standard care10 mg once daily72 hoursn = 108

    Acetazolamide eased breathlessness more in acute heart failure

    Clinical pharmacology and therapeutics

  2. Dapagliflozin showed no clear effect on NT-proBNP in humans (Stable PAH or CTEPH; compared with placebo) (Interaction p=0.39).

    “or NT-proBNP trajectory through week 4 and 12 (mixed model, interaction p=0.39).”

    Human trialStable PAH or CTEPH; compared with placebo10 mg daily4 and 12 weeksn = 52

    Dapagliflozin did not clearly improve exercise capacity

    ESC Congress 2026 abstract

  3. Dapagliflozin increases NT-proBNP in humans (type 2 diabetes without heart failure, on metformin monotherapy at recruitment) (+20% from baseline; p=0.07).

    “whereas it increased by 20% in the dapagliflozin group (p=0.07).”

    Human trialtype 2 diabetes without heart failure, on metformin monotherapy at recruitmentplasma6 monthsn = 92

    Effects of semaglutide and dapagliflozin on natriuretic peptides in type 2 diabetes: a randomized comparative study

    ESC Congress 2026 abstract

  4. Dapagliflozin decreases NT-proBNP in humans (-142 pg/mL (95% CI -324 to 41)).

    “The estimated intervention-versus-baseline difference was −142 pg/mL (95% CI −324–41) for NT-proBNP, 24.3 m (95% CI −2.8 to 51.5) for 6MWT distance, and 0.4 points (95% CI −4.0 to 4.8) for KCCQ-TSS.”

    Human trial12 weeksn = 7

    Using dapagliflozin to reduce symptoms in transthyretin cardiac amyloidosis: An n-of-1 trial series pilot study

    PloS one

  5. Dapagliflozin decreases NT-proBNP in patients with HFrEF combined with T2DM.

    “while their fasting plasma glucose, 2-h postprandial glucose, glycosylated hemoglobin, insulin resistance index, left ventricular end-systolic diameter, left ventricular end-diastolic diameter, cardiac troponin I, creatine kinase-MB, N-terminal pro b-type natriuretic peptide, serum creatinine, and blood urea nitrogen were significantly lower”

    Human trialin patients with HFrEF combined with T2DM

    Dapagliflozin in heart failure and type 2 diabetes: Efficacy, cardiac and renal effects, safety

    World journal of diabetes

  6. Dapagliflozin is linked with lower NT-proBNP in humans (28.4% reduction versus 8.7% reduction in controls).

    “NT-proBNP levels in the SGLT-2 inhibitor group exhibited a substantial 28.4% reduction”

    HumansHFpEF; combined with standard guideline-directed therapy versus standard guideline-directed therapy alone6 monthsn = 58

    SGLT-2 inhibitor dapagliflozin improves left ventricular diastolic function and reduces circulating inflammatory markers in HFpEF patients: a retrospective cohort study

    American journal of translational research

  7. Dapagliflozin is linked with lower NT-proBNP in humans during doxorubicin therapy in breast cancer patients with type 2 diabetes (+57.000 [95% CI +28.302, +85.698]).

    “lower NT-proBNP levels (+ 57.000 [95% CI + 28.302, + 85.698]) compared with the non-dapagliflozin group (p < 0.001)”

    Humansduring doxorubicin therapy in breast cancer patients with type 2 diabetes3 monthsn = 60

    Cardioprotective effects of dapagliflozin against doxorubicin-induced cardiotoxicity in breast cancer patients with type 2 diabetes: a prospective study

    BMC cancer

  8. Dapagliflozin is linked with lower NT-proBNP in humans (heart failure with preserved ejection fraction) (p = 0.046 and p = 0.039).

    “NT-proBNP and BNP levels showed significantly greater reductions in the dapagliflozin group (p = 0.046 and p = 0.039, respectively).”

    Humansheart failure with preserved ejection fractionn = 215

    Efficacy and Safety of Dapagliflozin in Patients Over 75 Years Old With Heart Failure With Preserved Ejection Fraction: A Retrospective Study

    British journal of hospital medicine (London, England : 2005)

More on NT-proBNP

Left ventricular ejection fraction

upin humans6upin mice1

7 studies
  1. Dapagliflozin increases left ventricular ejection fraction in humans (patients with sepsis receiving standardized treatment) (Median 60.0% versus 55.0% in controls).

    “On the 5th day of treatment, the median LVEF was significantly higher in the intervention group”

    Human trialpatients with sepsis receiving standardized treatmentheart10 mg5 days

    A preliminary study on the protective effect of dapagliflozin on multi-organ function in the early stage of sepsis

    Zhonghua nei ke za zhi

  2. Dapagliflozin increases left ventricular ejection fraction in humans (non-diabetic patients with AMI after PCI) (52.24% vs 47.66%).

    “Group I demonstrated superior cardiac improvement: higher LVEF (52.24 % vs. 47.66 %; p = 0.025)”

    Human trialnon-diabetic patients with AMI after PCIleft ventricle6 months

    Early Dapagliflozin in Non-diabetic Acute Myocardial Infarction Patients Post-PCI: Effects on Cardiovascular Outcomes and Left Ventricular Remodeling (EARLY DAPA-AMI)

    Journal of the Saudi Heart Association

  3. Dapagliflozin improves left ventricular ejection fraction in patients with HFrEF combined with T2DM.

    “After treatment, the pancreatic beta-cell function index, left ventricular ejection fraction, and glomerular filtration rate of patients in the study group were significantly higher than control group (P < 0.001)”

    Human trialin patients with HFrEF combined with T2DM

    Dapagliflozin in heart failure and type 2 diabetes: Efficacy, cardiac and renal effects, safety

    World journal of diabetes

  4. Dapagliflozin is linked with better left ventricular ejection fraction in HFrEF and HFpEF patients (+3.2% in HFrEF, +0.9% in HFpEF).

    “LVEF increased in HFrEF (+3.2%) and HFpEF (+0.9%).”

    Humansin HFrEF and HFpEF patients3 months

    Dapagliflozin and ventricular repolarization across heart failure phenotypes

    Current medical research and opinion

  5. Dapagliflozin is linked with higher left ventricular ejection fraction in humans (+5.98 ± 7.39% points).

    “mean LVEF increased from baseline to follow-up by 5.98 ± 7.39% points among 213 patients with paired LVEF data (paired p < 0.001)”

    Humansn = 213

    Real-world utilization, safety, and observed clinical outcomes of dapagliflozin among Sudanese patients with heart failure: a multicenter retrospective cohort study

    Scientific reports

  6. Dapagliflozin is linked with higher left ventricular ejection fraction in humans (2DE: 36.6±8.8 vs. 34.5±7.7%; 3DE: 37.4±8.7 vs. 34.4±7.9%; p < 0.001).

    “After 6MFU, left ventricular (LV) end-diastolic and end-systolic volumes reduced, and LVEF increased”

    HumansHeart failure with reduced ejection fraction on guideline-directed therapy; before-and-after comparisonheart10 mg daily6 monthsn = 75

    DAPAgliflozin-Related Cardiac REverse Remodeling by 2D and 3D Echocardiography in OptiMally Treated HFrEF Patients: The DAPA-REM Study

    Echocardiography (Mount Kisco, N.Y.)

  7. Dapagliflozin improves left ventricular ejection fraction in mice (experimental myocardial infarction).

    “Consistently, echocardiography showed improved left ventricular ejection fraction and reduced ventricular dilation after MI.”

    Animalsexperimental myocardial infarctionheart

    Dapagliflozin attenuates post-infarction inflammation and remodeling via promoting metabolic reprogramming–driven cardiac lymphangiogenesis

    ESC Congress 2026 abstract

More on Left ventricular ejection fraction

Mortality

downin humans5upin chickens1no changein humans1+40% mortalityRR 0.67

7 studies
  1. Dapagliflozin showed no clear effect on mortality in humans (critically ill patients with acute kidney injury) (-1.9% (95% CI -14.5 to 10.7)).

    “Adjusted risk differences were - 1.9% (95% CI -14.5 to 10.7) for death”

    Human trialcritically ill patients with acute kidney injury28 daysn = 212

    Safety and outcomes of dapagliflozin initiation in critically ill patients with acute kidney injury: A post-hoc analysis of the defender trial

    Journal of critical care

  2. Dapagliflozin decreases mortality in humans.

    “As expected, absolute risks of the cardiovascular composite endpoint and all-cause mortality were higher among older participants.”

    Human trialmedian of 2.4 yearsn = 4,304

    Effects of Dapagliflozin in Chronic Kidney Disease Across the Spectrum of Age and by Sex

    Journal of general internal medicine

  3. Dapagliflozin is linked with lower mortality in humans after acute myocardial infarction, after matching (P = 0.033).

    “At a median follow-up of 211 days, all-cause mortality remained lower in the DAPA group than in the control group after matching (P = 0.033).”

    Humansafter acute myocardial infarction, after matchingmedian follow-up of 211 daysn = 2,607

    Effect of dapagliflozin on malignant ventricular arrhythmias in elderly after acute myocardial infarction: a propensity score-matched cohort study

    European journal of clinical pharmacology

  4. Dapagliflozin decreases mortality in humans (early initiation during hospitalization for acute heart failure versus standard therapy) (RR 0.67, 95% CI 0.52-0.86).

    “Dapagliflozin significantly reduced all-cause mortality (RR 0.67, 95% CI 0.52-0.86)”

    Reviewearly initiation during hospitalization for acute heart failure versus standard therapy10 mg once dailyn = 3,507

    Early Initiation of Dapagliflozin in Acute Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    Biomedicines

  5. Dapagliflozin increases mortality in chickens (40% mortality).

    “survival rates declining sharply (40% mortality) in the 2.5 mg/mL group”

    Animalswhole embryo1.0-2.5 mg/mL

    Embryotoxic and Oxidative Impact of Dapagliflozin: A Dose-Dependent Study Using a Chick Embryo Model

    Journal of applied toxicology : JAT

  6. Dapagliflozin decreases mortality in humans (HFrEF) (OR: 0.83, 95%CI: 0.69 to 0.98).

    “Dapagliflozin+triple therapy (SUCRA: 76.8%; OR: 0.83, 95%CI: 0.69 to 0.98) and ARNI+BB+MRA (SUCRA: 76.6%; OR: 0.83, 95%CI: 0.75 to 0.92) demonstrated significant reductions in all-cause mortality.”

    ReviewHFrEF

    Comparative efficacy and safety of different SGLT2 inhibitor-based combination strategies in HFrEF: a systematic review and network meta-analysis

    Frontiers in endocrinology

  7. Dapagliflozin decreases mortality in HFrEF (DAPA-HF trial).

    “only 2 reduced mortality (sacubitril/valsartan in the PARADIGM-HF trial and dapagliflozin in the DAPA-HF trial)”

    Reviewin HFrEF (DAPA-HF trial)

    Evidentiary Landscape of Heart Failure Therapies, Regulatory Decisions, and Translation Into Guidelines

    Journal of the American College of Cardiology

Proteinuria

downin humans4no changein humans1

5 studies
  1. Dapagliflozin decreases proteinuria in humans (compared with placebo).

    “Dapagliflozin significantly reduced proteinuria compared with placebo (P = .012) without significantly affecting eGFR.”

    Human trialcompared with placebo10 mg daily12 months

    Impact of dapagliflozin on bone mineral metabolism in non-diabetic patients with chronic kidney disease: a randomized, double-blind, placebo-controlled study

    Clinical kidney journal

  2. Dapagliflozin decreases proteinuria in humans (chronic kidney disease).

    “proteinuria was notably reduced in most patients, indicating a positive renal effect.”

    Human trialchronic kidney disease12 monthsn = 12

    Comprehensive treatment with dapagliflozin in elderly chronic kidney disease patients: Clinical efficacy and impact on body composition

    Journal of diabetes and its complications

  3. Dapagliflozin showed no clear effect on proteinuria in non-diabetic patients with chronic kidney disease, vs placebo (0·9% difference vs placebo (95% CI -16·6 to 22·1)).

    “6-week treatment with dapagliflozin did not affect proteinuria in patients with chronic kidney disease without diabetes”

    Human trialin non-diabetic patients with chronic kidney disease, vs placebo10 mg per day6 weeksn = 53

    Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial

    The lancet. Diabetes & endocrinology

  4. Dapagliflozin is linked with lower proteinuria in humans (glomerular disease patients compared with historical controls) (proteinuria fell 51.9% vs 22.2% in historical cohort; adjusted GMR 0.684).

    “Proteinuria fell by 51.9% under dapagliflozin and by 22.2% in the historical cohort; the adjusted geometric mean ratio (GMR) was 0.684 (95% CI 0.534–0.877; p = 0.003).”

    Humansglomerular disease patients compared with historical controls

    Real-World Renal Effects of Dapagliflozin in Bulgarian Patients with Glomerular Diseases: A Two-Year Comparative Cohort Study with Historical Controls

    Preprints.orgPreprint

  5. Dapagliflozin is linked with lower proteinuria in humans (compared with matched controls not receiving SGLT2 inhibitors) (median change -157 vs -12 mg/day; Hodges-Lehmann -171 mg/day (95% CI -310 to -32)).

    “Proteinuria decreased more in the dapagliflozin group than in controls”

    Humanscompared with matched controls not receiving SGLT2 inhibitorskidney10 mg/day12 monthsn = 30

    Effects of dapagliflozin on proteinuria, glycemic control, and treatment burden in diabetic kidney transplant recipients: a matched cohort study

    Acta diabetologica

More on Proteinuria

Hepatic steatosis

downin humans3upin chickens1

4 studies
  1. Dapagliflozin decreases hepatic steatosis in humans (MASLD; compared with aspirin 100 mg once daily) (CAP 260.35 ± 20.78 vs 271.48 ± 12.58 dB/m; p = 0.005).

    “Dapagliflozin significantly improved hepatic steatosis, reflected by lower CAP values compared to aspirin”

    Human trialMASLD; compared with aspirin 100 mg once dailyliver10 mg once daily6 monthsn = 80

    Anti-inflammatory versus metabolic therapy in MASLD: a randomized clinical trial of aspirin and dapagliflozin using fibroscan outcomes

    Naunyn-Schmiedeberg's archives of pharmacology

  2. Dapagliflozin decreases hepatic steatosis in T2DM patients with MASLD (-71.02 dB/m).

    “Significant reductions were observed in hepatic steatosis (CAP: 316.7 to 245.7 dB/m; mean change - 71.02 dB/m, 95% CI: -63.4 to - 78.6; p < 0.001)”

    Human trialin T2DM patients with MASLDliver10 mg daily12 monthsn = 50

    Efficacy of dapagliflozin on hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: a pre-specified single-arm analysis from a randomized controlled trial

    Diabetes research and clinical practice

  3. Dapagliflozin is linked with lower hepatic steatosis in humans (MASLD; added to standard of care) (CAP 310.2 to 287.0 dB/m).

    “CAP decreased from 314.7 to 278.7 dB /m with saroglitazar and from 310.2 to 287.0 dB /m with dapagliflozin”

    HumansMASLD; added to standard of careliver10 mg once daily25 weeksn = 27

    Comparative Efficacy and Safety of Saroglitazar and Dapagliflozin on Hepatic Steatosis and Glycemic Control in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease: A 25‐Week Prospective Multicenter Comparative Cohort Study

    Endocrinology, diabetes & metabolism

  4. Dapagliflozin induces hepatic steatosis in chickens.

    “Histological examination demonstrated hepatic steatosis, pulmonary emphysema, and cardiac inflammation, alongside neural apoptosis and vascular abnormalities.”

    Animalsliver1.0-2.5 mg/mL

    Embryotoxic and Oxidative Impact of Dapagliflozin: A Dose-Dependent Study Using a Chick Embryo Model

    Journal of applied toxicology : JAT

Blood pressure

downin humans2no changein humans1downin mice1

4 studies
  1. Dapagliflozin showed no clear effect on blood pressure in humans (vs placebo).

    “changes in systolic and diastolic blood pressure and concentrations of neurohormonal biomarkers did not differ significantly between dapagliflozin and placebo treatment”

    Human trialvs placebo10 mg per day6 weeksn = 53

    Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial

    The lancet. Diabetes & endocrinology

  2. Dapagliflozin decreases blood pressure in patients with hypertension and concomitant T2D, CKD, or HF.

    “synthesizes the current clinical evidence regarding the antihypertensive effects of dapagliflozin”

    Reviewin patients with hypertension and concomitant T2D, CKD, or HF

    Efficacy and mechanistic insights of dapagliflozin in hypertension management

    Clinical and experimental hypertension (New York, N.Y. : 1993)

  3. Dapagliflozin decreases blood pressure in mice.

    “DAPA significantly reduced both systolic blood pressure (SBP) and diastolic blood pressure (DBP) in mice”

    Animalssingle dosemales

    Dapagliflozin lowers blood pressure via regulating the sympathetic neural activity in the paraventricular nucleus of hypothalamus in normal mice

    Frontiers in endocrinology

  4. Dapagliflozin decreases blood pressure in humans (type 2 diabetes mellitus).

    “Dapagliflozin also lowers blood pressure due to its natriuresis effect.”

    Reviewtype 2 diabetes mellitus

    Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus

    Cureus

Cognitive function

upin humans1no changein humans1upin mice1upin reviews1

4 studies
  1. Dapagliflozin improves cognitive function in humans (type 2 diabetes mellitus and mild cognitive impairment).

    “After 36 weeks, the dapagliflozin group demonstrated significant improvements in MoCA and MMSE scores compared to the control group.”

    Human trialtype 2 diabetes mellitus and mild cognitive impairment36 weeks

    The research of dapagliflozin on cognitive function in middle-aged and older patients with type 2 diabetes mellitus and mild cognitive impairment: a 36-week prospective parallel control study

    European journal of pharmacology

  2. Dapagliflozin showed no clear effect on cognitive function in humans (head-to-head comparison with liraglutide).

    “Our head-to-head study demonstrated that liraglutide enhanced impaired brain activation and restored impaired cognitive domains in patients with type 2 diabetes, whereas dapagliflozin and acarbose did not.”

    Human trialhead-to-head comparison with liraglutide16 weeksn = 36

    Enhancement of Impaired Olfactory Neural Activation and Cognitive Capacity by Liraglutide, but Not Dapagliflozin or Acarbose, in Patients With Type 2 Diabetes: A 16-Week Randomized Parallel Comparative Study

    Diabetes care

  3. Dapagliflozin improves cognitive function in experimental models.

    “We summarize preclinical evidence suggesting that dapagliflozin can improve cognitive performance and modulate pathways such as AMPK-mTOR”

    Reviewin experimental models

    Dapagliflozin and cognitive impairment: pharmacological mechanisms, translational evidence, and future directions

    Frontiers in pharmacology

  4. Dapagliflozin improves cognitive function in mice (HFD/STZ-induced T2DM mice).

    “dapagliflozin could significantly reduce fasting blood glucose levels, alleviate weight loss, and improve cognitive function performance in behavioral tests”

    AnimalsHFD/STZ-induced T2DM mice

    Dapagliflozin regulates kynurenine metabolism and microglial activation to alleviate diabetes-associated cognitive impairment

    Toxicology and applied pharmacology

Skeletal muscle mass

downin humans2no changein humans1downin rats1

4 studies
  1. Dapagliflozin decreases skeletal muscle mass in humans.

    “ASM / height2 decreased from 6.72 ± 0.87 to 6.62 ± 0.87 kg/m2 (P = 0.002), whereas ASM/weight did not change (29.0 ± 4.0 to 29.1 ± 3.9%, P = 0.33).”

    Human trial4 weeksn = 36

    Changes in glycemic control and skeletal muscle mass indices after dapagliflozin treatment in individuals with type 1 diabetes mellitus

    Journal of diabetes investigation

  2. Dapagliflozin showed no clear effect on skeletal muscle mass in humans (compared with non-SGLT2i medicines).

    “The absolute change in soft lean mass and skeletal muscle mass was not significantly different between groups.”

    Human trialcompared with non-SGLT2i medicinesskeletal muscle5 mg/daysix monthsn = 50

    Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes

    Journal of atherosclerosis and thrombosis

  3. Dapagliflozin is linked with lower skeletal muscle mass in humans (over approximately six months, in older adults with type 2 diabetes) (skeletal muscle mass index 11.68 ± 1.01 to 11.38 ± 0.88 kg/m2, p = 0.039).

    “While dapagliflozin was associated with slight muscle mass loss, empagliflozin preserved muscle.”

    Humansover approximately six months, in older adults with type 2 diabetesskeletal muscleapproximately six monthsn = 22

    Differential effects of dapagliflozin and empagliflozin on skeletal muscle mass in older adults with type 2 diabetes

    Endocrine

  4. Dapagliflozin decreases skeletal muscle mass in high-fat diet and streptozotocin-induced diabetic rats.

    “DAPA alone administration led to a decrease in skeletal muscle mass, whereas RT significantly increased skeletal muscle mass”

    Animalsin high-fat diet and streptozotocin-induced diabetic ratsskeletal musclesix weeksmales

    Exercise mitigates Dapagliflozin-induced skeletal muscle atrophy in STZ-induced diabetic rats

    Diabetology & metabolic syndrome

All 447

What is dapagliflozin linked with?

78

Studies link dapagliflozin with 78 measures, among them genital infections, dementia and hypoglycemia.

Genital infections

upin humans3

3 studies
  1. Dapagliflozin raises the risk of genital infections in humans (Patients with diabetes mellitus undergoing TAVR).

    “Genital infections were more frequent with dapagliflozin in patients with DM”

    Human trialPatients with diabetes mellitus undergoing TAVR12 monthsn = 537

    Valve trial found benefit in patients with diabetes and heart failure

    Cardiovascular diabetology

  2. Dapagliflozin raises the risk of genital infections in humans (dapagliflozin vs placebo, added to open-label metformin) (3.3% vs 0%).

    “events suggestive of vulvovaginitis, balanitis, and related genital infection in 3.3 vs. 0%”

    Human trialdapagliflozin vs placebo, added to open-label metformin10 mg/d24 wk

    Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin

    The Journal of clinical endocrinology and metabolism

  3. Dapagliflozin raises the risk of genital infections in humans (type 2 diabetes).

    “Patients in older adults with diabetes took a higher risk of genital infection and renal impairment or failure after treatment of dapagliflozin.”

    Reviewtype 2 diabetes

    Insights into efficacy and safety of dapagliflozin treatment for the management in older adults with type 2 diabetes: a systematic review and meta-analysis

    Expert opinion on drug safety

More on Genital infections

Dementia

downin humans2downin reviews1HR 0.75

3 studies
  1. Dapagliflozin is linked with a lower risk of dementia in humans (compared with DPP-4 inhibitors) (aHR 0.67 (95% CI 0.53-0.84)).

    “dapagliflozin exhibited the lowest risk (aHR 0.67 [95% CI 0.53-0.84])”

    Humanscompared with DPP-4 inhibitorsmean follow-up 2.80 years

    Association of Sodium-Glucose Cotransporter 2 Inhibitors With Time to Dementia: A Population-Based Cohort Study

    Diabetes care

  2. Dapagliflozin lowers the risk of dementia in humans (network meta-analysis versus other antidiabetic medications or placebo) (HR 0.75, 95% CrI 0.59–0.98).

    “Dapagliflozin (HR = 0.75, 95% CrI: 0.59, 0.98), and Empagliflozin (HR = 0.69, 95% CrI: 0.55, 0.85) significantly reduced the risk of dementia onset.”

    Reviewnetwork meta-analysis versus other antidiabetic medications or placebo

    Association between different sodium-glucose co-transporter 2 inhibitors and the risk of dementia: a network meta-analysis

    Frontiers in endocrinology

  3. Dapagliflozin lowers the risk of dementia in observational studies.

    “distinguishing observational studies that suggest lower dementia risk from randomized clinical evidence”

    Reviewin observational studies

    Dapagliflozin and cognitive impairment: pharmacological mechanisms, translational evidence, and future directions

    Frontiers in pharmacology

More on Dementia

Hypoglycemia

upin humans1downin humans1downin silico1RR 2.32

3 studies
  1. Dapagliflozin raises the risk of hypoglycemia in patients with type 2 diabetes on combination antihypertensive therapy (RR 2.32 (95% CI 1.11 to 4.82)).

    “The risk of hypoglycemia was higher in the dapagliflozin group (RR: 2.32; 95% CI 1.11; 4.82; p = 0.024).”

    Reviewin patients with type 2 diabetes on combination antihypertensive therapyn = 27,486

    MON-306 Effects of Dapagliflozin on Blood Pressure and Glycemic Control in Patients with Type 2 Diabetes on Combination Antihypertensive Therapy: A Systematic Review and Meta-Analysis

    ENDO 2025 abstract

  2. Dapagliflozin lowers the risk of hypoglycemia in humans (type 2 diabetes).

    “treatment with dapagliflozin reduced the risk of hypoglycemia”

    Reviewtype 2 diabetes

    Insights into efficacy and safety of dapagliflozin treatment for the management in older adults with type 2 diabetes: a systematic review and meta-analysis

    Expert opinion on drug safety

  3. Dapagliflozin lowers the risk of hypoglycemia in silico (simulated treatment-naive Chinese patients with type 2 diabetes, Cardiff Diabetes Model) (lower incidence).

    “dapagliflozin had lower incidences of cardiovascular events, hypoglycemia and mortality events”

    In silicosimulated treatment-naive Chinese patients with type 2 diabetes, Cardiff Diabetes Model40 years

    Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China

    PloS one

More on Hypoglycemia

Hospitalization for heart failure

downin humans2RR 0.57–0.75

2 studies
  1. Dapagliflozin lowers the risk of hospitalization for heart failure in humans (Prediabetes and heart failure; compared with placebo) (RR 0.75, 95% CI 0.58–0.98, p = 0.036).

    “SGLT-2 inhibitors reduced hospitalization for heart failure compared with placebo, including dapagliflozin (RR 0.75, 95% CI 0.58–0.98, p = 0.036)”

    ReviewPrediabetes and heart failure; compared with placebo

    Cardiovascular Effects of a Broad Range of Interventions for Adults with Prediabetes: A Systematic Review of Randomized Controlled Trials

    Medical sciences (Basel, Switzerland)

  2. Dapagliflozin lowers the risk of hospitalization for heart failure in humans (Heart failure with mildly reduced or preserved ejection fraction; compared with exenatide) (RR 0.57, 95% CI 0.36-0.91).

    “dapagliflozin (RR 0.57, 95% CI 0.36-0.91), empagliflozin (RR 0.54, 95% CI 0.34-0.86), and semaglutide (RR 0.43, 95% CI 0.20-0.91) were related to decreased risk of HF hospitalization.”

    ReviewHeart failure with mildly reduced or preserved ejection fraction; compared with exenatide

    Comparative Effects of Pharmacological Treatment on Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials

    Drugs

Urinary tract infection

downin humans1upin humans1RR 0.52

2 studies
  1. Dapagliflozin is associated with urinary tract infection in a patient with heart failure.

    “developed a urinary tract infection and subsequent septic shock following the initiation of dapagliflozin”

    Humansin a patient with heart failure2 months before presentationfemales

    Septic shock from urinary tract infection associated with sodium-glucose cotransporter 2 inhibitor in a high-risk patient with heart failure: A case report

    The Journal of international medical research

  2. Dapagliflozin lowers the risk of urinary tract infection in humans (early initiation during hospitalization for acute heart failure versus standard therapy) (RR 0.52, 95% CI 0.35-0.76).

    “Dapagliflozin significantly reduced all-cause mortality (RR 0.67, 95% CI 0.52-0.86) and urinary tract infections (RR 0.52, 95% CI 0.35-0.76)”

    Reviewearly initiation during hospitalization for acute heart failure versus standard therapy10 mg once dailyn = 3,507

    Early Initiation of Dapagliflozin in Acute Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    Biomedicines

More on Urinary tract infection

Cardiovascular death

upin humans1downin humans1+4.6% patients

2 studies
  1. Dapagliflozin lowers the risk of cardiovascular death in humans (joint frailty model) (hazard ratio 0.81 (95% CI 0.67-0.98)).

    “for cardiovascular death, the hazard ratio was 0.81 (95% CI, 0.67-0.98), P=0.0282”

    Human trialjoint frailty model

    Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF

    Circulation

  2. Dapagliflozin is associated with cardiovascular death in humans (4.6% of patients).

    “Cardiovascular death was observed in 4.6% of patients”

    Humans

    Real-world utilization, safety, and observed clinical outcomes of dapagliflozin among Sudanese patients with heart failure: a multicenter retrospective cohort study

    Scientific reports

Sarcopenia

upin humans2

2 studies
  1. Dapagliflozin is linked with a higher risk of sarcopenia in humans.

    “a risk of sarcopenia with Dapagliflozin use”

    Humans

    Exploring SGLT-2 inhibitors and sarcopenia in FAERS: a post-marketing surveillance study

    Expert opinion on drug safety

  2. Dapagliflozin is associated with sarcopenia in humans after oral antidiabetes drugs, including dapagliflozin, were initiated.

    “She also lost substantial bodyweight and developed sarcopenia.”

    Humansafter oral antidiabetes drugs, including dapagliflozin, were initiatedfemales

    Sodium-glucose cotransporter 2 inhibitor and sarcopenia in a lean elderly adult with type 2 diabetes: A case report

    Journal of diabetes investigation

More on Sarcopenia

Mortality

downin humans1downin silico1

2 studies
  1. Dapagliflozin lowers the risk of mortality in humans.

    “Similar to the primary composite outcome, dapagliflozin reduced the incidence of the kidney composite endpoint, cardiovascular composite endpoint, and all-cause mortality across all FI categories.”

    Human trialn = 4,303

    Efficacy and Safety of Dapagliflozin in Patients With Chronic Kidney Disease Across the Spectrum of Frailty

    The journals of gerontology. Series A, Biological sciences and medical sciences

  2. Dapagliflozin lowers the risk of mortality in silico (simulated treatment-naive Chinese patients with type 2 diabetes, Cardiff Diabetes Model) (lower incidence).

    “dapagliflozin had lower incidences of cardiovascular events, hypoglycemia and mortality events”

    In silicosimulated treatment-naive Chinese patients with type 2 diabetes, Cardiff Diabetes Model40 years

    Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China

    PloS one

Contrast-induced acute kidney injury

downin humans1OR 0.23

1 study
  1. Dapagliflozin lowers the risk of contrast-induced acute kidney injury in humans (OR 0.23, 95% CI 0.09–0.59).

    “The incidence was significantly lower in the dapagliflozin group than in the placebo group (6/161 [3.7%] vs. 23/161 [14.3%]; odds ratio [OR], 0.23; 95% confidence interval, 0.09–0.59; p = 0.001 by Fisher’s exact test).”

    Human trialbeginning 3 days before CCTA and continuing until completion of the 72-h post-CCTA follow-upn = 322

    Short-Term Peri-Procedural Dapagliflozin for Prevention of Contrast-Induced Acute Kidney Injury in Diabetic Patients Undergoing Coronary Computed Tomographic Angiography: A Prospective Randomized Double-Blind Placebo-Controlled Study

    Cardiorenal medicine

  2. Dapagliflozin lowers the risk of contrast-induced acute kidney injury in humans (diabetic patients scheduled for CCTA) (6/161 [3.7%] vs. 23/161 [14.3%]).

    “CI-AKI occurred in 29 patients overall (9.0%), with a significantly lower incidence in the dapagliflozin group than in the placebo group (6/161 [3.7%] vs. 23/161 [14.3%]; odds ratio, 0.23”

    Human trialdiabetic patients scheduled for CCTA10 mg once dailybeginning 3 days before CCTA through 72-h post-CCTAn = 322

    Short-Term Peri-Procedural Dapagliflozin for Prevention of Contrast-Induced Acute Kidney Injury in Diabetic Patients Undergoing Coronary Computed Tomographic Angiography: A Prospective Randomized Double-Blind Placebo-Controlled Study

    Cardiorenal medicine

More on Contrast-induced acute kidney injury

Higher E/e' quartile

downin humans1OR 0.325

1 study
  1. Dapagliflozin lowers the risk of higher E/e' quartile in humans (OR = 0.325, 95% CI: 0.152–0.692).

    “Finally, treatment with Dapagliflozin reduces by 67% the chance of being in a higher quartile of E/e’ (OR = 0.325, 95% CI: 0.152–0.692, p = 0.003) (Supplementary Table, Primary analysis).”

    Human trial12 weeksn = 98

    Dapagliflozin-induced integrated improvements in left ventricular diastole, endothelial function, and arterial load: a randomized clinical trial

    Cardiovascular diabetology

  2. Dapagliflozin lowers the risk of higher E/e' quartile in humans (type 2 diabetes) (OR 0.325, 95% CI 0.147-0.715).

    “Dapagliflozin treatment was associated with a 67% lower likelihood of being in a higher E/e' quartile (OR 0.325; 95% CI 0.147-0.715; p = 0.005).”

    Human trialtype 2 diabetes10 mg daily vs glibenclamide 5 mg12 weeksn = 96

    Dapagliflozin-induced integrated improvements in left ventricular diastole, endothelial function, and arterial load: a randomized clinical trial

    Cardiovascular diabetology

Sustained eGFR decline, ESKD, or death from kidney or cardiovascular causes

downin humans1HR 0.5

1 study
  1. Dapagliflozin lowers the risk of sustained eGFR decline, ESKD, or death from kidney or cardiovascular causes in humans.

    “Compared with placebo, dapagliflozin reduced the risk of primary composite endpoint across all categories of FI with HRs of 0.50 (95% CI, 0.33–0.76), 0.62 (95% CI, 0.45–0.85), and 0.64 (95% CI, 0.49–0.83) in not-to-mildly, moderately, and severely frail categories, respectively.”

    Human trialn = 4,303

    Efficacy and Safety of Dapagliflozin in Patients With Chronic Kidney Disease Across the Spectrum of Frailty

    The journals of gerontology. Series A, Biological sciences and medical sciences

  2. Dapagliflozin lowers the risk of sustained eGFR decline, ESKD, or death from kidney or cardiovascular causes in patients with chronic kidney disease across frailty levels (HR 0.50 (95% CI 0.33-0.76), 0.62 (0.45-0.85), and 0.64 (0.49-0.83) across FI categories).

    “Dapagliflozin reduced the risk of the primary composite endpoint across all FI categories”

    Human trialin patients with chronic kidney disease across frailty levels10 mg/day

    Efficacy and Safety of Dapagliflozin in Patients With Chronic Kidney Disease Across the Spectrum of Frailty

    The journals of gerontology. Series A, Biological sciences and medical sciences

Worsening heart failure event or cardiovascular death

downin humans1HR 0.74–0.82

1 study
  1. Dapagliflozin lowers the risk of worsening heart failure event or cardiovascular death in humans (HR 0.82, 95% CI 0.73–0.92).

    “In the overall trial, the HR for the primary composite end point with dapagliflozin compared with placebo was 0.82 (95% CI, 0.73–0.92”

    Human trialmedian follow-up of 2.3 yearsn = 6,263

    Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial

    Circulation

  2. Dapagliflozin lowers the risk of worsening heart failure event or cardiovascular death in humans (FI class 3 (most frail)) (HR 0.74, 95% CI 0.61-0.91).

    “The effect of dapagliflozin (as a hazard ratio) on the primary end point from FI class 1 to 3 was 0.85 (95% CI, 0.68-1.06), 0.89 (0.74-1.08), and 0.74 (0.61-0.91), respectively”

    Human trialFI class 3 (most frail)

    Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial

    Circulation

All-cause death or worsening heart failure

downin humans1HR 0.53

1 study
  1. Dapagliflozin lowers the risk of all-cause death or worsening heart failure in humans (Frail patients after transcatheter aortic valve implantation) (HR 0.53, 95% CI 0.36–0.77).

    “Dapagliflozin was associated with a lower risk of the primary end point in patients who were frail (HR, 0.53 [95% CI, 0.36-0.77])”

    Human trialFrail patients after transcatheter aortic valve implantation12 months

    Dapagliflozin may help frail patients more after valve replacement

    Journal of the American Heart Association

Composite kidney outcomes

downin humans1RR 0.71

1 study
  1. Dapagliflozin lowers the risk of composite kidney outcomes in humans (compared with semaglutide) (RR 0.71, 95% CI 0.53–0.94).

    “Dapagliflozin was associated with a lower risk of the composite kidney outcome than semaglutide (RR 0.71, 95% CI: 0.53-0.94)”

    Human trialcompared with semaglutide

    Comparative Cardiorenal Efficacy and Safety of Finerenone, SGLT2 Inhibitors, Semaglutide and Their Combination in Diabetic Kidney Disease

    Diabetes, obesity & metabolism

More on Composite kidney outcomes

Genitourinary infections

upin humans1

1 study
  1. Dapagliflozin raises the risk of genitourinary infections in humans.

    “although genitourinary infections were more frequent with dapagliflozin”

    Human trial10 mg once daily1 year

    Treatment effects of dapagliflozin in patients with aortic stenosis undergoing transcatheter aortic valve implantation across left ventricular ejection fraction

    European journal of heart failure

More on Genitourinary infections

All 78

Has dapagliflozin been tested in people?

124 of 406 about aging

Yes: 107 trials and 135 observational studies in people have been published, and 391 trials are registered.

Latest change Prostatic neoplasm: Phase 1 → Phase 2Oct 29, 2026

Approved

  • EMA Forxiga

    Nov 11, 2012Diabetes Mellitus, Type 2, Heart Failure, Systolic, Heart Failure, Renal Insufficiency, Chronic, Chronic Kidney Disease, chronic heart failure, controlled type 2 diabetes mellitus

  • FDA Farxiga

    Jan 8, 2014Diabetes Mellitus, Type 2, Heart Failure, Chronic Kidney Disease, End-stage Kidney Disease

  • EMA Edistride

    Nov 9, 2015Diabetes Mellitus, Type 2, Heart Failure, Systolic, Heart Failure, Renal Insufficiency, Chronic, Chronic Kidney Disease, chronic heart failure

  • EMA Dapagliflozin Viatris

    Mar 24, 2023Diabetes Mellitus, Type 2, Heart Failure, Systolic, Heart Failure, Renal Insufficiency, Chronic, Chronic Kidney Disease, chronic heart failure with reduced ejection fraction

Repurposing

40 of 117

Every condition in trials

  • TYPE2 diabetes

    Phase 4Status unknown3 trials

  • Motor Activity

    Phase 4Results posted2 trials

  • Diabetic nephropathy type 2

    Phase 4Completed1 trial

  • MASH metabolic dysfunction associated steatohepatitis

    Phase 4Recruiting1 trial

  • Autosomal dominant polycystic kidney

    Phase 3Recruiting1 trial

  • Health condition 1: E119- type 2 diabetes mellitus without complications

    Phase 3Recruiting1 trial

All 19

Stopped

  • NCT02608905TerminatedType 2 diabetes

    Due to difficulty with enrollment of subjects

  • NCT03152084TerminatedType 2 diabetes

    Poor recruitment.

  • NCT03344341TerminatedType 2 diabetes

    Study overall progress behind of scheduled timeline. Study was terminated early due to company decision.

  • NCT03660683TerminatedType 2 diabetes

    Sponsor did not want to continue funding the study

  • NCT05139914TerminatedType 2 diabetes

    The study was halted early because of the inability to enroll participants.

  • NCT04330079TerminatedPrediabetic state

    Slow enrollment. (Difficulty in selecting subjects)

All 11

Who is developing dapagliflozin?

3 companies: AstraZeneca, Emerald Clinical and THPharm.

Companies
  • AstraZenecaPhase 4chronic kidney disease, type 2 diabetes
  • Emerald ClinicalPhase 4type 2 diabetes, impaired renal function
  • THPharmPhase 3type 2 diabetes, hypertension

Trial sponsors

Funding

9 grants since 2019

National Institute of Diabetes and Digestive and Kidney Diseases$2.3MOffice of the President, University of California$2.4MSão Paulo Research Foundation

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Dapagliflozin improves healthspan in a fly study and reduces heart failure events in human trials. Independent labs reproduce reduced oxidative stress in mice, but HbA1c results differ across human trials. Aging-related trials are registered; across all uses, some trials ended over a year ago without posted results, and papers declare ties to developer and funder AstraZeneca.

  2. Summary rewritten as its findings changed.

    As it read before

    Dapagliflozin reduces senescence in mice across independent labs and improves healthspan in a fly study; a human trial shows no clear senescence effect. Human trials report fewer heart failure events and reduced chronic kidney disease, but a trial shows no clear cardiovascular mortality effect. Some human papers declare ties to developer AstraZeneca.

  3. Summary rewritten as its findings changed.

    As it read before

    Dapagliflozin reduces cellular senescence in mice across independent labs, but a human trial shows no clear effect on senescence. Human trials report lower mortality and fewer heart failure events. There are 124 aging-related trials; across all uses, 103 trials ended over a year ago without posted results or citing papers. AstraZeneca funds studies, and developers sponsor trials.

  4. Summary rewritten as its findings changed.

    As it read before

    Independent labs reproduce reduced cellular senescence in mice with dapagliflozin, while a human trial reports no change; one group reports improved fly healthspan. Human trials report fewer heart failure events; a trial finds no cardiovascular mortality change. Developers sponsor 161 trials; 63 trials concern aging, and 100 across all uses ended over a year ago without posted results or citing papers.

  5. Summary rewritten as its findings changed.

    As it read before

    Dapagliflozin reduces senescence in human cells across independent labs; human trials report fewer heart-failure events and slower CKD progression, while fly healthspan improves but aged-killifish lifespan does not. HbA1c results differ; 41 registered trials concern aging, while 100 across uses ended over a year ago without posted results. AstraZeneca funds work and has author ties; developer companies sponsor 158 trials across uses.

Latest

Dec 2025: 17Jan 2026: 36Feb 2026: 42Mar 2026: 40Apr 2026: 3May 2026: 7Jun 2026: 13Jul 2026: 15Aug 2026: 30Sep 2026: 24Oct 2026: 77Nov 2026: 55359 papers in 12 months

See all 518 papers on dapagliflozin